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Abstract
Background: Emergence of coronavirus disease 2019 (COVID-19) is a major health-
care threat. Apparently, the novel coronavirus (SARS-CoV-2) is armed by special 
abilities to spread and dysregulate the immune mechanisms. The likelihood of oro-
pharyngeal candidiasis (OPC) development in COVID-19 patients with a list of attrib-
utable risk factors for oral infections has not yet been investigated.
Objectives: We here aim to investigate the prevalence, causative agents and antifun-
gal susceptibility pattern of OPC in Iranian COVID-19 patients.
Patients and Methods: A total of 53 hospitalised COVID-19 patients with OPC were 
studied. Relevant clinical data were mined. Strain identification was performed by 
21-plex PCR and sequencing of the internal transcribed spacer region (ITS1-5.8S-
ITS2). Antifungal susceptibility testing to fluconazole, itraconazole, voriconazole, am-
photericin B, caspofungin, micafungin and anidulafungin was performed according to 
the CLSI broth dilution method.
Results: In 53 COVID-19 patients with OPC, cardiovascular diseases (52.83%) and 
diabetes (37.7%) were the principal underlying conditions. The most common risk 
factor was lymphopaenia (71%). In total, 65 Candida isolates causing OPC were re-
covered. C albicans (70.7%) was the most common, followed by C glabrata (10.7%), 
C dubliniensis (9.2%), C parapsilosis sensu stricto (4.6%), C tropicalis (3%) and Pichia 
kudriavzevii (=C krusei, 1.5%). Majority of the Candida isolates were susceptible to all 
three classes of antifungal drugs.
Conclusion: Our data clarified some concerns regarding the occurrence of OPC in 
Iranian COVID-19 patients. Further studies should be conducted to design an ap-
propriate prophylaxis programme and improve management of OPC in critically ill 
COVID-19 patients.
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1  | INTRODUC TION
Since December 2019, an unprecedented outbreak of viral pneu-
monia caused by an initially unknown viral pathogen linked to a 
seafood associated wholesale market emerged in Wuhan, Hubei 
Province, China.1,2 The pathogen of the disease was soon iden-
tified as a novel coronavirus (SARS-CoV-2), and the disease was 
named coronavirus disease-19 (COVID-19).3 Despite global con-
tainment and quarantine attempts, the incidence continued to 
increase, spread to many other countries and caused a pandemic 
with a great number of deaths.4 The mortality rate differs greatly 
from country to country.5 Among various factors leading to mor-
bidity and mortality in COVID-19 patients, the prevalence and 
role of bacterial and fungal co-infections has not yet been dis-
cussed, particularly in patients suffering from acute respiratory 
distress syndrome (ARDS). So far, inadequate attention has been 
given to the prevalence of fungal infections in patients suffering 
from COVID-19 that may experience lymphocytopaenia, hospi-
talisation in intensive care unit (ICU), broad-spectrum antibiotic 
and corticosteroid usage, intubation, cytokine storms, and hav-
ing underlying diseases which make them severely immunocom-
promised.5-9 Due to undefined pharmacological treatment for 
COVID-19, indirect complex effect, invasive therapeutic meth-
ods and multi-drug treatment, some pathological oral conditions 
can be expected to be aggravated by SARS-CoV-2, particularly in 
those patients with a compromised immune mechanism, or that 
take long-term pharmacotherapies.10 For these reasons, they are 
at substantial risk for developing mucosal candidiasis. Based on 
our centre experiences in the management of severely COVID-
19 patients, oropharyngeal candidiasis (OPC) might be a probable 
cause of morbidity in these patients that begins with colonisation 
of the Candida species on the oral mucosa. Consequently, local 
discomfort, an altered taste sensation, oral burning, glossodynia, 
dysphagia and difficulty in breathing may be felt by the patients.11 
In the majority of cases, this opportunistic yeast infection is en-
dogenously acquired and develops when local host defences are 
weakened.12,13 Candida albicans is the most important species 
(>80%) that causes OPC.9 Nonetheless, non-albicans species, 
such as C tropicalis, C glabrata, C parapsilosis, Pichia kudriavzevii 
(=C krusei) and C dubliniensis, are also known to contribute to 
this infection.9 In case of untreated, ineffective treatment, OPC 
caused by fluconazole-resistant Candida species or in patients 
with an immunocompromised status, the infection can regionally 
spread from the oropharynx to the oesophagus or systematically 
through the bloodstream or upper gastrointestinal tract leading 
to candidemia with significant morbidity and mortality.11 Hence, 
timely detection of OPC and accurate identification of aetiologi-
cal agents in patients suffering from COVID-19 are important to 
optimise effective therapy and improvement of outcome. So far, 
the likelihood of OPC development, as the most prevalent mu-
cocutaneous mycosis of the oral cavity in severe COVID-19 pa-
tients, has not yet been investigated. Therefore, the current study 
was conducted to investigate the prevalence, causative agents 
and antifungal susceptibility pattern of OPC in Iranian COVID-19 
patients.
2  | MATERIAL S AND METHODS
2.1 | Study design, patients and specimens
This cross-sectional study was undertaken from 1 March 2020 
to 30 April 2020 on all patients with clinically and laboratory 
confirmed COVID-19 infections at three tertiary care training 
hospitals (Imam Khomeini hospital complex, Ziaeian hospital and 
Hazrat Rasoul Akram hospital) affiliated with Tehran University 
of Medical Sciences and Iran University of Medical Sciences, 
Tehran, Iran. Verbal consent was obtained from patients before 
being enrolled in this study. The protocol of this study was in 
accordance with the principals established by the Declaration of 
Helsinki and was approved by the ethics committee of Tehran 
University of Medical Sciences, Tehran, Iran (IR.TUMS.VCR.
REC.1399.058). The oral cavity of patients was examined for 
OPC, and those with clinically confirmed OPC representing by 
finding pseudomembranous structures or white plaques on the 
intraoral mucous layer, with or without other complaints such as 
dry mouth and glossalgia, were included in this study. The de-
mographic and clinical data were documented in the patients’ 
sheets. Sampling was carried out from oral plaques using sterile 
swabs. OPC was confirmed by the presence of budding yeast and 
pseudohyphae in KOH 10% preparation and culture. The swabs 
were streaked on Sabouraud dextrose agar (Difco Laboratories, 
Detroit, Mich) plates on bedside. Plates were incubated at 37°C 
and checked daily.
2.2 | Phenotypic and molecular identification
For obtaining pure single colonies and preliminary identifica-
tion, the grown yeast isolates were subcultured on CHROMagar 
Candida medium (CHROMagar, Paris, France). Accurate identi-
fication of isolates was based on a 3-step 21-plex PCR method 
using primers and conditions described previously.14,15 A set 
of standard strains of common Candida species were included 
as controls. To identify isolates with inconclusive results in the 
21-plex PCR, the ITS1-5.8S rDNA-ITS2 region was amplified 
using primers ITS1: 5′-TCCGTAGGTGAACCTGCGG-3′ and ITS4: 
5′-TCCTCCGCTTATTGATATGC-3′ using conditions described 
previously.16 PCR amplicons were sequenced, and results were 
analysed using NCBI BLAST (https://www.blast.ncbi.nlm.nih.gov/
Blast.cgi) and ISHAM barcoding (http://its.mycol ogylab.org) data-
bases. The ITS1-5.8S rDNA-ITS2 sequences of isolates have been 
deposited in the GenBank (eg an accession number for each spe-
cies; MT640021 to MT640028).
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2.3 | Antifungal susceptibility testing
Antifungal susceptibility patterns of isolates to three classes of 
antifungal drugs, that is azoles (fluconazole, voriconazole and itra-
conazole), polyenes (amphotericin B) and echinocandins (caspo-
fungin, anidulafungin and micafungin), were assessed according to 
the fourth edition of the Clinical and Laboratory Standards Institute 
M27 standard method.17 Stock solutions of drugs were prepared in 
DMSO and diluted in RPMI-1640 medium (Gibco) to obtain 2× the 
final concentrations. The final concentrations ranged from 0.015 to 
8 µg/mL for echinocandins, 0.031 to 16 µg/mL for amphotericin B, 
itraconazole and voriconazole, and 0.125 to 64 µg/mL for flucona-
zole. Hundred µLs of serial dilutions of drugs were dispensed into 
columns 1 to 10 of 96-well microtiter plates, and the plates were 
stored at −80°C until their use. Fungal inoculum was prepared using 
fresh colonies and adjusted to a transmittance within the range 75%-
77% at 530 nm wavelength. Resulting suspensions were diluted 1:20 
and then 1:100 in RPMI-1640 medium to obtain working inoculums. 
Subsequently, 100 µL of suspensions were added to all wells of test 
plates except for the column 11 which was assigned as inoculum-
free negative control. Column 12 was used as drug-free growth con-
trol. Plates were incubated at 35°C, and results were visually read 
after 24 hours in comparison to growth control wells. C parapsilosis 
(ATCC 22019) and Pichia kudriavzevii (ATCC 6258) standard strains 
were used as quality control. The minimum inhibitory concentrations 
(MICs) were interpreted according to the breakpoints or epidemio-
logical cut-off values (ECV) provided in CLSI M60 and M59 supple-
ments.18,19 Results of itraconazole against C albicans, C dubliniensis 
and C parapsilosis were interpreted according to the values estab-
lished by Pfaller et al.20
2.4 | Statistical analysis
All statistical analyses were performed using SPSS v24 (SPSS Inc). 
Descriptive test was performed to describe the demographic char-
acteristics, and chi-square test was performed on all variables of this 
study. Statistical significance was assumed with P = .05.
3  | RESULTS
3.1 | Patient characteristics
During the period of this study, 53 (5%) out of 1059 Iranian pa-
tients with confirmed COVID-19 infection had OPC. The patients 
were within an age range of 27 to 90 years with a mean ± SD 
of 63.1 ± 16.4 years. Almost 80% of the patients (n = 42) were 
≥50 years of age, which was significantly associated with OPC 
(P = .03). Females (30/53; 56.6%) were slightly more affected than 
males (43.4%) by OPC. The mean ± SD time interval between di-
agnosis of COVID-19 and clinical presentations of OPC leading 
to specimen collection was 8 days (range: 1-30 days) (Figure 1). 
F I G U R E  1   Hospitalised time between diagnosis of COVID-19 
and clinical presentations of OPC
TA B L E  1   Demographic and clinical characteristics of 










Cardiovascular diseases 28 52.8
Diabetes 20 37.7








Corticosteroid therapy 25 47
Admission to ICU 26 49








Prolonged fever 39 73.5
Respiratory distress 50 94.3
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Infectious ward (15/53; 28.3%) and Thorax ward (12/53; 22.6%) 
contained the highest number of patients. The demographics 
and background clinical data of patients are shown in Table 1. 
Cardiovascular diseases (28/53; 52.8%) and diabetes (20/53; 
37.7%) were the principal underlying conditions in COVID-19 pa-
tients with OPC. Seventy-one per cent of patients suffering from 
COVID-19 infection with OPC showed lymphopaenia (a median 
lymphocyte count of 1000 cells/mm) (P < .001). Due to the si-
multaneous occurrence of COVID-19 infection and OPC, vari-
ous drugs including antiviral (53/53; 100%), antibacterial (49/53; 
92.5%) and antifungal (52/53; 98.1%) as well as corticosteroids 
(25/53; 47.1%) were administered. Methylprednisolone (18/53; 
33.9%) was the main corticosteroid prescribed to patients, fol-
lowed by hydrocortisone (5/53; 9.4%) and dexamethasone (4/53; 
7.5%). Regarding antifungal drugs, except for 1 (1.8%) patient who 
did not receive any treatment, 21 (39.6%), 13 (24.5%) and 1 (1.8%) 
patients were treated by fluconazole, nystatin and caspofungin, 
respectively. The remaining 17 (32%) patients were given a com-
bination of fluconazole and nystatin. The mean ± SD duration of 
antifungal treatment was 4.79 ± 2.11 days.
3.2 | Distribution of Candida species
In total, 65 Candida isolates causing OPC were recovered from 53 
patients. Mixed infections were observed in 9 cases (6 cases of co-
infection by two and 3 cases by three Candida species). C albicans 
(46/6; 70.7%) was the most prevalent yeast species. Among the main 
non-albicans Candida (NAC) species, C glabrata (7/65; 10.7%) was the 
predominant species, followed by C dubliniensis (6/65; 9.2%), C par-
apsilosis sensu stricto (3/65; 4.6%), C tropicalis (2/65; 3%) and P kudri-
avzevii (1/65; 1.5%).
3.3 | Antifungal susceptibility testing
The distribution of Candida isolates based on the MIC values of an-
tifungal drugs, the MIC ranges, MIC50, geometric mean (GM) and 
percentage of susceptible/wild-type isolates is shown in Table 2. In 
general, there was a high level of susceptibility to all the tested an-
tifungal drugs. Amphotericin B (overall MIC range: 0.016-0.25 µg/
mL, GM: 0.027 µg/mL, MIC50: 0.016 µg/mL), anidulafungin (overall 
MIC range: 0.008-0.062 µg/mL, GM: 0.014 µg/mL, MIC50: 0.016 µg/
mL) and micafungin (overall MIC range: 0.008-0.016 µg/mL, GM: 
0.009 µg/mL, MIC50: 0.008 µg/mL) were the most active drugs, and 
no case of resistance to these antifungal drugs was noted. The overall 
narrowest and widest MIC ranges were observed for anidulafungin 
and micafungin (0.008-0.016 µg/mL) and caspofungin (0.008-2 µg/
mL), respectively. All isolates were susceptible/wild-type to flucona-
zole (overall MIC range: 0.125-1 µg/mL), except for one P kudriavzevii 
isolate (MIC: 4 µg/mL), a species that is intrinsically resistant, and 
one isolate of C dubliniensis (MIC: 2 µg/mL). For voriconazole, two 
out of 46 (4.35%) C albicans isolates were intermediate, while the 
remaining isolates were susceptible. Caspofungin was the least ac-
tive drug. The only isolate of P kudriavzevii (MIC: 2 µg/mL) and one 
isolate of C dubliniensis (MIC: 1 µg/mL) were caspofungin-resist-
ant. Furthermore, two out of 46 (4.35%) C albicans isolates and all 
C glabrata isolates were intermediate to this drug.
4  | DISCUSSION
An enveloped novel coronavirus caused a global pandemic burden 
with life-threatening outcomes.7,10,21 Apparently, the virus is armed 
by special abilities to spread and dysregulate the immune mecha-
nisms.22 Several studies have addressed the probability of occurrence 
of fungal co-infections, particularly invasive pulmonary aspergillosis 
in COVID-19 patients.5,23-29 Furthermore, due to several risk factors, 
COVID-19 patients are also vulnerable to infections caused by the 
emerging species, C auris.30 During our multicentre experiences in 
the management of patients with COVID-19, we found that pseu-
domembranous white plaques and erythematous areas occurred in 
the oral mucosa of 5% of hospitalised patients with COVID-19 and 
on average occurred within 8 days of onset of COVID-19. Our data 
showed that OPC is more probably to infect older adult COVID-19 
patients with cardiovascular diseases and diabetes status as a result 
of weaker immune functions of these patients. Similarly, in previ-
ous studies, cerebrovascular diseases and diabetes were the main 
reported chronic underlying diseases in patients with COVID-19, 
which were more common among patients with severe disease and 
were associated with poor prognosis.6,31 We found that increasing 
age (≥50 years) was significantly associated with OPC among COVID-
19 patients. In a cross-sectional study, Suryana et al revealed that 
increasing age (P = .03) was significantly identified risk factor in HIV 
patients.32 Elderly patients were shown to have significantly lower 
activity levels of protective salivary innate defences.33 Considering 
the clinical course, disease progression and severity of COVID-19, 
most of COVID-19 patients with critically ill conditions inevitably ex-
perience at least one of following risk factors, for OPC, including lym-
phocytopaenia, ICU admission, invasive or non-invasive ventilation, 
corticosteroid and broad-spectrum antibiotic usage or having immu-
nocompromised condition which give them a significantly increased 
risk for the development of opportunistic fungal infections.5,6,11,22,34 
In our descriptive study, broad-spectrum antibiotic therapy, lympho-
cytopaenia, ICU admission, systemic corticosteroids usage and me-
chanical ventilation were documented as the most frequent factors 
predisposed our subjects with COVID-19 to develop OPC. However, 
these findings need to be verified by a comparative case control study 
in the future to accurately identify the risk factors for OPC in patients 
with COVID-19. Broad-spectrum antibiotic usage was the most asso-
ciated risk factors for the development of OPC in COVID-19 patients 
as it occurred in nearly 92.5 of our subjects. Dysbiosis by bacterial 
depletion due to the use of broad-spectrum antibiotics can alter 
the local oral flora, creating a favourable environment for Candida 
to proliferate.35 In a study from Chinese hospitals, the usage rate of 
antibiotics and antifungal agents in patients with severe COVID-19 
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was 100% and 39%, respectively.36 It is noteworthy that lymphocyte 
counts were found to be below the normal range in nearly 63%-85% 
of patients with COVID-19 indicating lymphocytopaenia (approxi-
mately 63%-83%) as the main laboratory finding.6,7,22,31 The possible 
reason for the high rate of OPC in lymphocytopaenic patients can 
be attributed to lymphocytes consumption by the virus; especially, T 
lymphocytes as was also documented in infections caused HIV and 
SARS-CoV resulting in a substantial decrease of the total number of 
lymphocytes and, subsequently, result in an immunocompromised 
status of the patients.10,22,37 A former study has shown that 16% of 
COVID-19 patients were admitted to the ICU and 8.3% underwent 
invasive ventilation.6 Du and coworkers reported that 39% of su-
perinfections were evidenced in COVID-19 patients hospitalised in 
ICUs in China.36 Different groups of anti-inflammatory medications 
for treatment of patients with severe COVID-19 pneumonia are fre-
quently used, although with conflicting information regarding their 
efficacy.7,10 Oral exposure to topical or systemic corticosteroids is 
another common cause of medication associated oral candidiasis, 
probably due to alterations of the local mucosal immunity.9,11,38 In 
agreement with previous studies,6,7 47.2% of our COVID-19 patients 
with OPC had a history of corticosteroids use. In the current study, 
C albicans (70%) and NAC species (30%) were isolated from COVID-
19 patients with OPC. These data are in agreement with the find-
ings of previous OPC reports.13,35,39 NAC isolates are remarkable 
pathogenic agents involved in OPC, which is of relevance to decide 
on the selection of therapeutics for this infection.35,40 Interestingly, a 
high percentage of C dubliniensis was observed in our patients, which 
is similar to those reported in OPC caused by NAC species in HIV-
infected patients.13,37 In general, there was a high level of susceptibil-
ity to all the tested antifungal drugs. The increasing use of fluconazole 
to treat OPC and the emergence of azole resistance have resulted in 
a change in the prevalence of different Candida species.41 Long-term 
use of azoles may lead to the selection of less sensitive species, such 
as P kudriavzevii, C dubliniensis and C glabrata, and the development of 
resistance in previously susceptible Candida strains.37 In conclusion, 
our data clarified some concerns regarding the occurrence of OPC 
in Iranian COVID-19 patients. Data from our centres can contribute 
to decide on more effective strategies in antifungal treatments and 
to design an appropriate prophylaxis programme for the benefit of 
such patients.
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